Key Takeaways
- IBRX shares surged 17.50%, closing at $11.55 on February 24, 2026, up from a prior close of $9.83.
- The primary catalyst was the company's Q4 2025 earnings report, which beat both EPS and revenue consensus estimates.
- ImmunityBio reported approximately $113 million in full-year 2025 net product revenue — a roughly 700% year-over-year increase — driven by the rapid adoption of its ANKTIVA immunotherapy.
- H.C. Wainwright raised its price target on IBRX to $15 from $10, while other analysts maintained bullish ratings with targets as high as $24.
- A high short interest (~40% of float) and shrinking share availability added short-squeeze pressure to the rally.
- Trading volume exceeded 83 million shares, roughly triple the average daily volume, reflecting powerful institutional and retail conviction.
Opening Summary
ImmunityBio, Inc. (IBRX) is a commercial-stage biotechnology company headquartered in San Diego, California, focused on developing next-generation immunotherapies and cell therapies to treat cancers and infectious diseases. Its lead product, ANKTIVA, is an FDA-approved immunotherapy used in combination with BCG for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
On Monday, February 24, 2026, IBRX rallied 17.50%, closing at $11.55, up from a prior close of $9.83. The stock traded as high as $12.28 during the session — touching a near 52-week high — before pulling back slightly into the close. The move was driven by a combination of strong Q4 earnings results, continued ANKTIVA sales momentum, analyst price target increases, expanded global regulatory approvals, and intensifying short-squeeze dynamics.
Q4 2025 Earnings Beat
The primary catalyst was ImmunityBio's Q4 2025 earnings report, released before the market open. The company posted a loss of $0.06 per share, beating the Zacks consensus estimate of -$0.08 — an earnings surprise of approximately 25–33%. Quarterly revenue came in at approximately $38.3 million, surpassing estimates of roughly $37.8 million and representing a 431% increase compared to Q4 2024.
For the full year 2025, ANKTIVA generated approximately $113 million in net product revenue, reflecting a remarkable 700% year-over-year increase. Unit sales volume growth of 750% underscored accelerating clinical adoption of the bladder cancer treatment. Q4 revenue also rose 20% sequentially from Q3, illustrating consistent commercial traction.
Analyst Upgrades and Price Target Increases
The earnings beat prompted several analyst actions that further fueled buying pressure. H.C. Wainwright raised its price target on IBRX to $15 from $10 while maintaining a Buy rating, citing ANKTIVA's $113 million revenue milestone and expanded European reach across 33 countries. D. Boral Capital reiterated a Strong Buy rating with a $24 price target, implying over 100% upside from current levels. The consensus among five analysts stood at Strong Buy with an average target of approximately $11.60.
Expanded Global Regulatory Approvals
Beyond the earnings beat, ImmunityBio's growing international footprint added another layer of bullish sentiment. The Saudi Food and Drug Authority (SFDA) had approved ANKTIVA for both BCG-unresponsive NMIBC-CIS and, notably, for metastatic non-small cell lung cancer (NSCLC) in combination with immune checkpoint inhibitors — marking the world's first approval of an IL-15 superagonist in combination with checkpoint therapy.
The European Commission also granted conditional marketing authorization for ANKTIVA in NMIBC-CIS across 33 EU countries, following the EMA recommendation. The company opened an Irish subsidiary to support its European commercial launch. These regulatory milestones significantly expand ANKTIVA's total addressable market beyond the United States.
Short Squeeze Dynamics
A major amplifier of the February 24 rally was the stock's extremely high short interest. Approximately 40% of the tradable float was sold short, and with IBRX hitting a new one-year high at $12.28, short sellers faced mounting losses. Available shares to borrow on Interactive Brokers dropped from 400,000 to just 10,000, and borrowing utilization hit 100%. Days to cover stood at approximately 4.65, meaning shorts would need nearly five full trading days to unwind their positions at current volumes — creating a classic squeeze setup where forced buying compounds upward pressure.
Market Context and Trading Activity
Volume on February 24 surged to over 83 million shares, roughly 2.7 times the average session volume of approximately 30 million shares. This marked the sixth consecutive day of gains for IBRX, extending a powerful rally that has seen the stock roughly quintuple in 2026 alone.
The broader biotech sector provided a supportive backdrop, as investor appetite for oncology names with commercial-stage revenue growth remained strong. IBRX traded well above both its 50-day and 200-day moving averages, which had been at $4.50 and $3.02 respectively in recent weeks, confirming a sustained uptrend. The stock's intraday high of $12.28 nearly matched its 52-week high, a technically significant level that attracted momentum traders.
Trending AI Robots
For traders looking to capitalize on volatile biotech moves like IBRX, Tickeron offers a curated selection of AI-powered trading bots through its Trending AI Robots page. Tickeron maintains hundreds of AI trading robots covering thousands of tickers across diverse strategies, timeframes, and risk profiles. The Trending AI Robots section highlights only the top-performing bots under current market conditions, giving traders a filtered, data-driven starting point. Bots vary by approach — from swing trading and day trading to momentum and mean-reversion strategies — and each is scored on real-time performance metrics. Traders seeking systematic, algorithm-driven approaches to navigating fast-moving stocks may find this resource worth exploring.
What Comes Next for IBRX
Several catalysts lie ahead for ImmunityBio. Enrollment in the Phase 2b QUILT-2.005 trial evaluating ANKTIVA plus intravesical BCG in BCG-naïve non-muscle invasive bladder cancer has surpassed 85% and is expected to reach full enrollment in the first half of 2026, potentially supporting a Biologics License Application (BLA) to the FDA by year-end. BCG-naïve data expected in the second half of 2026 could represent another significant label expansion opportunity.
The company also plans to submit a regulatory package for its recombinant BCG therapy in Saudi Arabia and to conduct three additional clinical trials over the next three years evaluating ANKTIVA in new indications, including combinations with CAR-NK/M-ceNK cell therapy and for lymphopenia treatment.
Key risks include the company's continued lack of profitability — the $0.06 per-share loss, while narrowing, signals ongoing cash burn. The $10 billion market capitalization is substantial for a company still in its early commercial phase, and the elevated short interest suggests that a meaningful contingent of investors remains skeptical. Any setback in clinical trials, regulatory decisions, or a deceleration in ANKTIVA sales growth could trigger significant volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.